Acrivastine

Revision as of 18:05, 9 June 2009 by Brian Blank (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

{{drugbox | | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image = | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank = | C = 22 | H = 24 | N = 2 | O = 2 | molecular_weight = 348.438 g/mol | smiles = CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 1.5 hours | excretion = Renal | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = }}

WikiDoc Resources for Acrivastine

Articles

Most recent articles on Acrivastine

Most cited articles on Acrivastine

Review articles on Acrivastine

Articles on Acrivastine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acrivastine

Images of Acrivastine

Photos of Acrivastine

Podcasts & MP3s on Acrivastine

Videos on Acrivastine

Evidence Based Medicine

Cochrane Collaboration on Acrivastine

Bandolier on Acrivastine

TRIP on Acrivastine

Clinical Trials

Ongoing Trials on Acrivastine at Clinical Trials.gov

Trial results on Acrivastine

Clinical Trials on Acrivastine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acrivastine

NICE Guidance on Acrivastine

NHS PRODIGY Guidance

FDA on Acrivastine

CDC on Acrivastine

Books

Books on Acrivastine

News

Acrivastine in the news

Be alerted to news on Acrivastine

News trends on Acrivastine

Commentary

Blogs on Acrivastine

Definitions

Definitions of Acrivastine

Patient Resources / Community

Patient resources on Acrivastine

Discussion groups on Acrivastine

Patient Handouts on Acrivastine

Directions to Hospitals Treating Acrivastine

Risk calculators and risk factors for Acrivastine

Healthcare Provider Resources

Symptoms of Acrivastine

Causes & Risk Factors for Acrivastine

Diagnostic studies for Acrivastine

Treatment of Acrivastine

Continuing Medical Education (CME)

CME Programs on Acrivastine

International

Acrivastine en Espanol

Acrivastine en Francais

Business

Acrivastine in the Marketplace

Patents on Acrivastine

Experimental / Informatics

List of terms related to Acrivastine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors.

It is sold under the brand name Benadryl Allergy Relief in the U.K. by Pfizer, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by Pfizer in the U.K. This drug is currently not available as a generic in the U.K. [1]

In the U.S., acrivastine is the active ingrediant in the Semprex brand. Semprex-D is also acrivastine based, but also contains a decongestant.

References

  1. Cheapest hayfever remedies 2007, Money Saving expert, May 15th,2007

Template:SIB da:Acrivastin sk:Acrivastin

Template:WH

Template:WS